More Articles

Five years of bioequivalence data from Cetero questioned Biosimilars/General | Posted 16/09/2011

FDA is challenging five years of bioequivalence and other studies conducted at Cetero Research’s Houston facility in the US. This could affect both originator and generics companies alike, putting...

Ranbaxy to launch generic atorvastatin on time Generics/News | Posted 16/09/2011

Ranbaxy Laboratories will release a generic version of the blockbuster cholesterol-lowering drug Lipitor (atorvastatin) in the US at the end of November 2011 as planned, according to a report in th...

Biosimilars and the pharmaceutical industry Biosimilars/Research | Posted 09/09/2011

IMS Health predicts a slowing down of the growth in annual spending on medicines, with generics being one of the main contributing factors for this reduction.

US drug shortages prompt oncologists to go into drug manufacture Generics/News | Posted 09/09/2011

Drug shortages in the US are at a record high and there appears to be no quick solution to the problem. Legislation, government stock-piling and physicians importing or even manufacturing drugs are...

Positive results for phase I trial of biosimilar erythropoietin Biosimilars/News | Posted 09/09/2011

Hospira, self-proclaimed leader in injectable generics, announced on 6 September 2011 positive results from a phase I clinical trial of its biosimilar erythropoietin (EPO) carried out in the US in...

The reference pricing system: a socio-economic analysis of the use of low cost medicines in Belgium Reports | Posted 09/09/2011

Medicines contribute to improving the health status of populations. A recent literature review concluded that medicines are among the most valuable forms of health care and are instrumental in trea...

Sanofi France to make generic atorvastatin Generics/News | Posted 09/09/2011

The French daily newspaper, Les Echos, reported on 1 September 2011 that sanofi France (sanofi) had reached an agreement with Pfizer to produce generic versions of the blockbuster cholesterol drug...

Opportunities for biosimilars in emerging markets Biosimilars/Research | Posted 09/09/2011

By 2015, IMS Health expects spending on biosimilars to exceed US$2 billion annually, or about 1% of total global spending on biologicals [1]. This growth in biosimilars will be driven mainly by pat...